Bridge Medicines Adds Small Molecule Inhibitors of Activated Factor XII to Pipeline Gallery

Bridge Medicines Adds Small Molecule Inhibitors of Activated Factor XII to Pipeline

Bridge Medicines Enters Exclusive License Agreement with The Rockefeller University for Novel Epigenetic Leukemia Program Gallery

Bridge Medicines Enters Exclusive License Agreement with The Rockefeller University for Novel Epigenetic Leukemia Program

Bridge Medicines Enters Agreement with Weill Cornell Medicine to Develop a Novel Sphingosine 1-Phosphate (S1P) Receptor Modulator Gallery

Bridge Medicines Enters Agreement with Weill Cornell Medicine to Develop a Novel Sphingosine 1-Phosphate (S1P) Receptor Modulator

Bridge Medicines Enters Agreement with Memorial Sloan Kettering to Develop Kidney‐Specific Delivery Platform for the Treatment of Acute Kidney Injury Gallery

Bridge Medicines Enters Agreement with Memorial Sloan Kettering to Develop Kidney‐Specific Delivery Platform for the Treatment of Acute Kidney Injury

Bridge Medicines Appoints Louis M. Renzetti, Ph.D., As Chief Scientific Officer Gallery

Bridge Medicines Appoints Louis M. Renzetti, Ph.D., As Chief Scientific Officer

Bridge Medicines Accepts Novel Small Molecule Targeting Basal Cell Carcinoma As First Drug Candidate for Development Gallery

Bridge Medicines Accepts Novel Small Molecule Targeting Basal Cell Carcinoma As First Drug Candidate for Development